Avalo Therapeutics AVTX Business Segments — Nonclinical expenses

Similar metrics at other companies

GPORReportable Segments — Other segment expenses

$2.3M+2,833%

HYMCReportable Segment — Segment Expenses

$15.1M+176%

CRCTotal Reportable Segments — Other segment expenses

$89M+45.9%

BRBRReportable Segment — Other segment expenses

$55.2M-12.2%

INBXReportable Segment — Other segment expenses

$5000.0%

BJReportable Segment — Other segment expenses

$1.18B+34.8%

FAQ

What is Avalo Therapeutics's business segments — nonclinical expenses?

Avalo Therapeutics (AVTX) reported business segments — nonclinical expenses of $249K in Q2 2026.

How has Avalo Therapeutics's business segments — nonclinical expenses changed year-over-year?

Avalo Therapeutics's business segments — nonclinical expenses increased by 39.1% year-over-year, from $179K to $249K.

What is the long-term trend for Avalo Therapeutics's business segments — nonclinical expenses?

Over 2 years (2023 to 2025), Avalo Therapeutics's business segments — nonclinical expenses has grown at a -10.5% compound annual growth rate (CAGR), from $1.03M to $825K.

What does business segments — nonclinical expenses mean?

Represents the costs associated with early-stage research activities, including laboratory studies and animal testing conducted prior to human clinical trials. These expenditures are critical for assessing the safety and efficacy profiles of drug candidates before regulatory approval for human testing. Monitoring these costs helps investors understand the company's investment in the foundational stages of its drug development pipeline.